Current therapeutic strategies for ccRCC focus on Tyrosine Kinase Inhibitors (such as sunitinib, sorafenib, pazopanib, axitinib) or other anti-angiogenic drugs (i.e. bevacizumab) to counteract VEGF/ PDGF upregulation in VHL mutated tumors with accumulated HIF1/2α [52]. This evidence concerns the gene HIF1A and nonpapillary renal cell carcinoma.